Merck & Co SEC Filings

Thomas H. Glocer, a director of Merck & Co., Inc. (MRK), reported transactions dated 09/30/2025. The filing shows a disposition of 5,100 shares of Merck common stock in the non-derivative section. In the derivative section, Mr. Glocer acquired 580.8412 phantom stock units on the same date; those units are to be settled 100% in cash upon his termination of service under the referenced deferred compensation plan. The phantom units represent 580.8412 underlying common shares with an indicated price of $83.93, and the report lists 105,645.8965 shares beneficially owned following the transactions. The form is signed by an attorney-in-fact for Mr. Glocer on 10/02/2025. The filing notes that holdings include shares acquired through dividend reinvestment.

Mary Ellen Coe, identified as a director of Merck & Co. (MRK), reported transactions dated 09/30/2025. The filing shows a disposition of 10 shares of Merck common stock and the acquisition of 357.4407 phantom stock units, each unit representing one share. The phantom units are tied to 357.4407 shares with a reference price of $83.93. The report lists total beneficial ownership following the transactions as 28,684.663 shares. The phantom units are to be settled 100% in cash upon the reporting person's termination of service under the plan's distribution schedule. The filing also notes holdings include shares from dividend reinvestment.

Merck & Co., Inc. is offering multiple series of unsecured notes totaling up to $6.0 billion across maturities from 2027 to 2055. The offering includes $500 million of floating rate notes maturing September 15, 2027 and five fixed-rate series: $750 million 3.850% due 2027, $750 million 4.150% due 2030, $1.0 billion 4.550% due 2032, $1.75 billion 4.950% due 2035 and $1.25 billion 5.700% due 2055. The notes are unsecured and will rank pari passu with other unsecured indebtedness and be structurally subordinated to liabilities of subsidiaries; as of June 30, 2025 certain subsidiaries had $5.7 billion of indebtedness and guaranteed $1.0 billion of parent debt. The floating rate notes reference Compounded SOFR and include detailed benchmark transition and replacement provisions; the prospectus warns of SOFR volatility, limited history and potential adverse effects if benchmark replacement occurs. The fixed-rate notes pay semiannual interest and may be optionally redeemed by the issuer under specified Treasury-rate-based formulas. The notes will be issued in book-entry form through DTC.

Merck & Co., Inc. prospectus supplement describes an offering of multiple series of unsecured notes, including floating rate notes tied to Compounded SOFR and several fixed-rate series. The notes will be issued in global, book-entry form through DTC and will not be listed on an exchange; currently there is no public market. The issuer is a finance subsidiary whose obligations will be unsecured and effectively junior to any secured debt and structurally subordinated to non‑guarantor subsidiaries' liabilities. The prospectus details SOFR-related volatility and benchmark transition risks, optional redemption mechanics for fixed-rate series, customary transfer and payment procedures, defeasance features, restrictive covenants (including limits on secured debt and sale-leaseback transactions) and events of default. Several key economic terms (aggregate sizes, exact interest rates, specific maturity dates and settlement dates) are redacted in the provided text.

Merck & Co. (MRK) Form 4 – 5 Aug 2025: EVP & Chief Information & Digital Officer David M. Williams reported the vesting of 17,119 restricted stock units (RSUs) on 4 Aug 2025 (code M). The shares were issued at the market price of $79.29 and immediately reduced by 8,432 shares (code F) that the issuer withheld to cover tax obligations. Net increase to Williams’s direct ownership is +8,687 shares, bringing his total direct holding to 33,013.467 shares. The related RSU grant is now fully settled; no derivative securities remain.

The footnote clarifies a prior filing error: the RSUs were previously disclosed as vesting in three annual tranches, but actually vested in one installment on 4 Aug 2025. No other transactions, sales to the open market, or new option grants were disclosed.